Trials / Conditions / Streptococcus Pneumoniae

Streptococcus Pneumoniae

27 registered clinical trials studyying Streptococcus Pneumoniae — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910	Institut Pasteur du Cambodge	—
Active Not Recruiting	A Study to Learn About How a New Pneumococcal Vaccine Works in Adults NCT07086677	Pfizer	Phase 1
Active Not Recruiting	Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections NCT06096025	Methodist Health System	—
Recruiting	Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus P NCT04460235	Poitiers University Hospital	Phase 4
Completed	An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, NCT04078997	University of Liverpool	—
Completed	Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Cent NCT02888457	Pierre Van Damme	N/A
Completed	PCV10 Immunogenicity Study Nepal 2015 NCT02385513	University of Oxford	Phase 4
Completed	Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years NCT02215863	Korea University Guro Hospital	Phase 4
Unknown	PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study NCT03064620	Sheba Medical Center	—
Completed	Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status NCT02141009	St. Antonius Hospital	Phase 4
Completed	Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine NCT01995617	Genocea Biosciences, Inc.	Phase 1
Completed	Neisseria Meningitidis Burden of Disease Study NCT01730391	GlaxoSmithKline	—
Suspended	Costa Rica Epidemiological Study on S. Pneumoniae NCT01308827	Instituto de Atención Pediátrica	—
Completed	Evaluating Vaccine Responses in Healthy Infants Receiving Their Routine Primary Immunisation According to the NCT01425372	Prof. Elizabeth Miller	—
Completed	Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan) NCT01521897	Pfizer	—
Completed	Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ NCT00907777	GlaxoSmithKline	Phase 3
Completed	Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disea NCT00861380	GlaxoSmithKline	Phase 3
Unknown	Impact of the 7 Valent Pneumococcal Conjugate Vaccine (7vPCV) on Nasopharyngeal Carriage of Streptococcus Pneu NCT00900978	German-Jordanian University	Phase 1 / Phase 2
Terminated	Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine NCT00849069	GlaxoSmithKline	Phase 1
Completed	Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age NCT00814710	GlaxoSmithKline	Phase 3
Completed	Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 102 NCT00839254	GlaxoSmithKline	Phase 3
Completed	Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults NCT00814489	GlaxoSmithKline	Phase 1
Completed	Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar NCT00594347	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Immunogenicity of PCV-7 Vaccine in VLBW Infants NCT00273325	NICHD Neonatal Research Network	—
Completed	Evaluation of the Immunogenicity and Reactogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults NCT00197821	Public Health England	Phase 2
Completed	Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting NCT00622843	Henry M. Jackson Foundation for the Advancement of Military Medicine	Phase 3
Completed	Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants NCT00197769	Public Health England	Phase 2